223 related articles for article (PubMed ID: 17881247)
1. Expression of tolerogenic HLA-G molecules in cancer prevents antitumor responses.
Rouas-Freiss N; Moreau P; Menier C; LeMaoult J; Carosella ED
Semin Cancer Biol; 2007 Dec; 17(6):413-21. PubMed ID: 17881247
[TBL] [Abstract][Full Text] [Related]
2. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape.
Algarra I; García-Lora A; Cabrera T; Ruiz-Cabello F; Garrido F
Cancer Immunol Immunother; 2004 Oct; 53(10):904-10. PubMed ID: 15069585
[TBL] [Abstract][Full Text] [Related]
3. Indoleamine 2,3 dioxygenase and human leucocyte antigen-G inhibit the T-cell alloproliferative response through two independent pathways.
Le Rond S; Gonzalez A; Gonzalez AS; Carosella ED; Rouas-Freiss N
Immunology; 2005 Nov; 116(3):297-307. PubMed ID: 16236119
[TBL] [Abstract][Full Text] [Related]
4. Trogocytosis-based generation of suppressive NK cells.
Caumartin J; Favier B; Daouya M; Guillard C; Moreau P; Carosella ED; LeMaoult J
EMBO J; 2007 Mar; 26(5):1423-33. PubMed ID: 17318190
[TBL] [Abstract][Full Text] [Related]
5. Immune-refractory cancers and their little helpers--an extended role for immunetolerogenic MHC molecules HLA-G and HLA-E?
Wischhusen J; Waschbisch A; Wiendl H
Semin Cancer Biol; 2007 Dec; 17(6):459-68. PubMed ID: 17768067
[TBL] [Abstract][Full Text] [Related]
6. Structure, expression and function of HLA-G in renal cell carcinoma.
Seliger B; Schlaf G
Semin Cancer Biol; 2007 Dec; 17(6):444-50. PubMed ID: 17707652
[TBL] [Abstract][Full Text] [Related]
7. Human leukocyte antigen-G in cancer: are they clinically relevant?
Yan WH
Cancer Lett; 2011 Dec; 311(2):123-30. PubMed ID: 21843913
[TBL] [Abstract][Full Text] [Related]
8. Soluble HLA-A,-B,-C and -G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation.
Contini P; Ghio M; Poggi A; Filaci G; Indiveri F; Ferrone S; Puppo F
Eur J Immunol; 2003 Jan; 33(1):125-34. PubMed ID: 12594841
[TBL] [Abstract][Full Text] [Related]
9. Interaction of indoleamine-2,3-dioxyagnase and CD4+CD25+ regulatory T cells in tumor immune escape.
Wang H; Pan K; Xia JC
Ai Zheng; 2009 Feb; 28(2):184-7. PubMed ID: 19550135
[TBL] [Abstract][Full Text] [Related]
10. Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma.
Bukur J; Rebmann V; Grosse-Wilde H; Luboldt H; Ruebben H; Drexler I; Sutter G; Huber C; Seliger B
Cancer Res; 2003 Jul; 63(14):4107-11. PubMed ID: 12874014
[TBL] [Abstract][Full Text] [Related]
11. Distinct effects of human glioblastoma immunoregulatory molecules programmed cell death ligand-1 (PDL-1) and indoleamine 2,3-dioxygenase (IDO) on tumour-specific T cell functions.
Avril T; Saikali S; Vauleon E; Jary A; Hamlat A; De Tayrac M; Mosser J; Quillien V
J Neuroimmunol; 2010 Aug; 225(1-2):22-33. PubMed ID: 20493562
[TBL] [Abstract][Full Text] [Related]
12. NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G.
Maki G; Hayes GM; Naji A; Tyler T; Carosella ED; Rouas-Freiss N; Gregory SA
Leukemia; 2008 May; 22(5):998-1006. PubMed ID: 18288133
[TBL] [Abstract][Full Text] [Related]
13. Human melanoma cell secreting human leukocyte antigen-G5 inhibit natural killer cell cytotoxicity by impairing lytic granules polarization toward target cell.
Lesport E; Baudhuin J; LeMaoult J; Sousa S; Doliger C; Carosella ED; Favier B
Hum Immunol; 2009 Dec; 70(12):1000-5. PubMed ID: 19654030
[TBL] [Abstract][Full Text] [Related]
14. Trophoblast cell line resistance to NK lysis mainly involves an HLA class I-independent mechanism.
Avril T; Jarousseau AC; Watier H; Boucraut J; Le Bouteiller P; Bardos P; Thibault G
J Immunol; 1999 May; 162(10):5902-9. PubMed ID: 10229826
[TBL] [Abstract][Full Text] [Related]
15. HLA-G expression in malignant melanoma.
Rebmann V; Wagner S; Grosse-Wilde H
Semin Cancer Biol; 2007 Dec; 17(6):422-9. PubMed ID: 17689098
[TBL] [Abstract][Full Text] [Related]
16. Regulatory role of tryptophan degradation pathway in HLA-G expression by human monocyte-derived dendritic cells.
López AS; Alegre E; LeMaoult J; Carosella E; González A
Mol Immunol; 2006 Jul; 43(14):2151-60. PubMed ID: 16490253
[TBL] [Abstract][Full Text] [Related]
17. Non-classical HLA-G antigen and its role in the cancer progression.
Tripathi P; Agrawal S
Cancer Invest; 2006 Mar; 24(2):178-86. PubMed ID: 16537188
[TBL] [Abstract][Full Text] [Related]
18. The role of HLA-G in gastrointestinal inflammatory disease and malignancy.
Downs-Kelly E; Schade AE; Hansel DE
Semin Cancer Biol; 2007 Dec; 17(6):451-8. PubMed ID: 17716911
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of HLA-G expression via RNAi abolishes resistance of extravillous trophoblast cell line TEV-1 to NK lysis.
Chen LJ; Han ZQ; Zhou H; Zou L; Zou P
Placenta; 2010 Jun; 31(6):519-27. PubMed ID: 20430441
[TBL] [Abstract][Full Text] [Related]
20. The major histocompatibility complex class Ib molecule HLA-E at the interface between innate and adaptive immunity.
Sullivan LC; Clements CS; Rossjohn J; Brooks AG
Tissue Antigens; 2008 Nov; 72(5):415-24. PubMed ID: 18946929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
